We have previously reported marked enhancement of anti-tumor efficacy of a DC-targeting melanoma vaccine by the addition of Interferon α (IFN) and 5’aza-2 deoxycytidine (5Aza) to the therapeutic regimen. Here, IFNA1 is linked to melanoma.